Remission in Adults With Mild-to-moderate Asthma in Thailand

April 15, 2026 updated by: Narongkorn Saiphoklang, MD, Thammasat University

The goal of this observational study is to determine the prevalence of remission among adults with mild-to-moderate asthma, as well as the factors associated with remission in Thailand.

The main question the study aims to answer is:

What is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete a questionnaire on asthma symptoms and undergo pulmonary function testing and a blood test once.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This study is a cross-sectional study. Thai patients aged 18 years or older with mild-to-moderate asthma are included in the study. Participants will complete two questionnaires about asthma control: the Global Initiative for Asthma (GINA) and the Asthma Control Test (ACT), and will perform spirometry, a fractional exhaled nitric oxide (FeNO) test, and blood eosinophil counts (BEC).

GINA and ACT are questionnaires used to assess the level of asthma control.

Study Type

Observational

Enrollment (Estimated)

289

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Thailand
      • Pathum Thani, Thailand, 12120
        • Recruiting
        • Faculty of Medicine, Thammasat University
        • Principal Investigator:
          • Narongkorn Saiphoklang, MD
        • Contact:
        • Contact:
    • Changwat Pathum Thani
      • Pathum Thani, Changwat Pathum Thani, Thailand, 12120
        • Recruiting
        • Narongkorn Saiphoklang
        • Contact:
        • Principal Investigator:
          • Narongkorn Saiphoklang, MD
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Thai patients aged 18 years or older with mild-to-moderate asthma are included in the study

Description

Inclusion Criteria:

  • mild-to-moderate asthma
  • age 18 years or older

Exclusion Criteria:

  • inability to perform spirometry or fractional exhaled nitric oxide (FeNO) test

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Mild-to-moderate asthma

Patients aged 18 years or older with mild-to-moderate asthma. Mild asthma refers to asthma patients who experience symptoms <3 times per week, have preserved lung function (FEV₁ or PEF >80% of predicted), and whose symptoms can be adequately controlled with low-dose inhaled corticosteroids (low-dose ICS) alone, without the need for long-acting bronchodilators or other controller medications.

Moderate asthma refers to asthma patients who have symptoms >4-5 days per week or experience nocturnal asthma symptoms >1 per week, and who require treatment with medium-dose inhaled corticosteroids (medium-dose ICS) or low-dose ICS in combination with a long-acting β₂-agonist (low-dose ICS/LABA) to achieve symptom control and prevent exacerbations.
Other: Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires
GINA and ACT are questionnaires used to assess the level of asthma control.
Other: Spirometry
Spirometry is a tool used to assess pulmonary function.
Other: Fractional exhaled nitric oxide (FeNO) test
FeNO is a tool used to assess eosinophilic airway inflammation and asthma remission.
Other: Blood eosinophil count (BEC)
BEC is a tool used to assess eosinophilic inflammation and asthma remission.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence rate of mild-to-moderate asthma remission
Time Frame: An average of 1 year
Prevalence rate of mild-to-moderate asthma remission (%)
An average of 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Asthma control in patients with mild-to-moderate asthma
Time Frame: At baseline and at 12 months
Rate of patients with well-controlled asthma. Well-controlled asthma is defined as an Asthma Control Test (ACT) score of 20 or higher.
At baseline and at 12 months
Airway obstruction in patients with mild-to-moderate asthma
Time Frame: At baseline and at 12 months
Airway obstruction is assessed using FEV1/FVC ratio on spirometry.
At baseline and at 12 months
Severity of aiway obstruction in patients with mild-to-moderate asthma
Time Frame: At baseline and at 12 months
The severity of aiway obstruction is assessed using FEV1 % predicted on spirometry.
At baseline and at 12 months
Eosinophil airway inflammation in patients with mild-to-moderate asthma
Time Frame: At baseline and at 12 months
Eosinophil airway inflammation is assessed using blood eosinophil count (cells/µL).
At baseline and at 12 months
Type 2 airway inflammation in patients with mild-to-moderate asthma
Time Frame: At baseline and at 12 months
Type 2 airway inflammation is assessed using fractional exhaled nitric oxide (FeNO, ppb).
At baseline and at 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Thammasat University

Investigators

  • Principal Investigator: Narongkorn Saiphoklang, MD, Thammasat University Faculty of Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2026

Primary Completion (Estimated)

October 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

January 10, 2026

First Submitted That Met QC Criteria

January 11, 2026

First Posted (Actual)

January 20, 2026

Study Record Updates

Last Update Posted (Actual)

April 17, 2026

Last Update Submitted That Met QC Criteria

April 15, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MTU-EC-IM-0-282/68

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IPD and documents will be available for sharing immediately after publication for a period of 2 years.

IPD Sharing Time Frame

IPD and documents will be available for sharing immediately after publication for a period of 2 years.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Asthma

Clinical Trials on Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe